Results 201 to 210 of about 138,725 (257)

Successful Treatment of Subcorneal Pustular Dermatosis with Abrocitinib

Acta Dermato-Venereologica
Zirui Chen, Jiahui Zhao, Hang Li
doaj   +1 more source

Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series. [PDF]

Intern Med
Hosomi S, Nishida Y, Fujiwara Y.
europepmc   +1 more source

Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib. [PDF]

J Clin Immunol
Dotta L, Todaro F, Baronio M, Giacomelli M, Pinelli M, Giambarda M, Brognoli B, Greco S, Rota F, Cortesi M, Soresina A, Moratto D, Tomasi C, Ferraro RM, Giliani S, Badolato R.   +15 more
europepmc   +1 more source

JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune-Related Colitis Triggered by CTLA-4 and PD-1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report. [PDF]

Cancer Rep (Hoboken)
Kono M, Komeda Y, Kawakami H, Hagiwara S, Tribonias G, Handa K, Omoto S, Takenaka M, Kashida H, Tsuji N, Kudo M.   +10 more
europepmc   +1 more source

Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial. [PDF]

Int J Hematol
Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, Maeda Y, Kondo T, Fujisaki T, Shoshi K, Azuma K, Fukushima R, Kawashima J, Kosugi H.   +13 more
europepmc   +1 more source

Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. [PDF]

Adv Ther
Harrison CN, Vannucchi AM, Recher C, Passamonti F, Gerds AT, Hernandez-Boluda JC, Yacoub A, Sirhan S, Ellis C, Patel B, Strouse B, Platzbecker U.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

JAK inhibitors for rheumatoid arthritis

Expert Opinion on Investigational Drugs, 2023
JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis. These inhibitors vary in their selectivity for different JAK isoforms.This review outlines the mode of actions and the results of Phase III trials of the JAK ...
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka   +2 more
openaire   +2 more sources

Selective JAK Inhibitors

Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock, Eugene Guorong, Yang, Yuyi, Chu-Farseeva, Lianbin, Yao   +3 more
openaire   +2 more sources